We then asked whether combination with ICB is required for systemic anti-tumor immunity and observed tumor-specific abscopal effects with the monotherapy or when combined with anti-PD-1 or anti-CTLA-4 (Fig. 1, G to I). This evidence concerns the gene PDCD1 and neoplasm.